Dr. Maldonado joins Koya as Chief Medical Officer and member of the Medical Advisory Board
Koya Medical (“Koya”), a medical technology company advancing evidence-based therapies for vascular disease, today announced the addition of Dr. Thomas Maldonado as Chief Medical Officer. The addition of Dr. Maldonado further strengthens Koya Medical’s clinical advisory board, led by Stanley Rockson, M.D., cardiologist and professor in the Falk Cardiovascular Research Center at Stanford University School of Medicine.
Thomas Maldonado, M.D. has been one of New York City’s top vascular surgeons in one of the nation’s premier academic medical centers for over two decades. He is regularly featured as Top Doctor by Castle Connolly and has served as president of numerous national and regional vascular societies. Dr. Maldonado, who is devoted to unrivaled patient care and research, states that he is “honored to serve as Chief Medical Officer for Koya Medical and looks forward to continuing to advance the Dayspring to help even more people with lymphedema and venous diseases maintain mobility while receiving effective compression treatment.”
Dr. Maldonado, Professor of Surgery, is a prolific researcher and academician with over 150 publications in the field of vascular surgery and serves as editor-in-chief for the journal, Vascular and Endovascular Surgery. Additionally, Dr. Maldonado is an innovator in minimally invasive endovascular therapy. He is nationally and internationally recognized for his surgical skill as well as his commitment to education and advancing patient care.
Dayspring is the first and only non-pneumatic active dynamic compression treatment designed for patient mobility and cleared by the U.S. Food and Drug Administration (FDA) to treat lymphedema and chronic venous conditions.
About Lymphedema
An estimated 20 million Americans live with lymphedema, a progressive, incurable condition where a buildup of protein rich fluid causes painful swelling in the arm, leg, and/or other regions of the body. For most, lymphedema requires lifelong maintenance and various levels of therapy to control swelling and pain. Lymphedema is commonly caused by cancer—such as breast cancer, uterine cancer, prostate cancer, vulvar cancer, ovarian cancer, lymphoma, melanoma and cancers of the head and neck—and its treatment due to damage of the lymph system from the tumor itself, radiation treatment or the surgical impairment of lymph nodes.1
About Koya Medical
Founded in 2018 and headquartered in Dallas, Koya Medical is a medical technology company developing a portfolio of evidence-based treatments designed to improve clinical outcomes and patient experience in vascular disease.
Reference:
1. What is lymphedema? American CancerSociety.https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/lymphedema/what-is-lymphedema.html.Accessed September 26, 2022.
